/content/mofsl-website-adobe/fragments/open-demat-popup
style
hide-in-desktop

US Stock Details

Get in-depth insights on US stocks, including fundamentals, financials, shareholding, peer comparison, and performance. Track key metrics, price trends, and market sentiment for informed decisions. Stay ahead with expert analysis and data-driven strategies at Motilal Oswal.

style
pb-0

Evolus, Inc.

us-stock
To Invest in {{usstockname}}
/content/mofsl-website-adobe/demat-form-fields
style
sticky-block,pt-0
us-stock
style
pt-0
$6.79 0.0353(3.53%) EOLS at 04 Dec 2025 04:30 PM Drug Manufacturers - Specialty & Generic
Lowest Today 6.56
Highest Today 6.77
Today’s Open 6.57
Prev. Close 6.52
52 Week High 17.12
52 Week Low 5.71
Day’s Range: Low 6.56 High 6.77
52-Week Range: Low 5.71 High 17.12
1 day return -
1 Week return -5.13
1 month return +5.14
3 month return -10.42
6 month return -31.24
1 year return -47.91
3 year return -3.5
5 year return +77.5
10 year return -

Institutional Holdings

BioPharma Credit Ord 8.75

Vanguard Total Stock Mkt Idx Inv 2.61

iShares Russell 2000 ETF 1.99

Schroder US Smaller Companies Acc 1.18

Oberweis Micro-Cap 1.05

Oberweis Micro-Cap Growth 1.05

Vanguard Institutional Extnd Mkt Idx Tr 0.84

Fidelity Small Cap Index 0.83

Invesco S&P 500 ETF 0.72

iShares Russell 2000 Growth ETF 0.72

Nuveen Quant Small Cap Equity R6 0.71

Frontier Small Cap Growth 0.66

CREF Stock R3 0.51

Altium Capital Management, LP 0.46

Fidelity Extended Market Index 0.42

Vanguard Russell 2000 ETF 0.39

JPMorgan US Small Company L 0.39

Schwab US Small-Cap ETF™ 0.36

State St Russell Sm Cap® Indx SL Cl I 0.31

SPDR® S&P Pharmaceuticals ETF 0.26

Schroder U.S. Small Cap Core 0.26

Market Status

Strong Buy: 4

Buy: 3

Hold: 0

Sell: 0

Strong Sell: 0

Fundamentals

Market Cap 422.62 M

PB Ratio 53.7058

PE Ratio 0.0

Enterprise Value 553.44 M

Total Assets 232.57 M

Volume 987514

Company Financials

Annual Revenue FY23:184732000 184.7M, FY22:148616000 148.6M, FY21:99673000 99.7M, FY20:56540000 56.5M, FY19:34925000 34.9M

Annual Profit FY23:129073000 129.1M, FY22:92729000 92.7M, FY21:56139000 56.1M, FY20:38241000 38.2M, FY19:26911000 26.9M

Annual Net worth FY23:-63018000 -63.0M, FY22:-74412000 -74.4M, FY21:-46810000 -46.8M, FY20:-163013000 -163.0M, FY19:-90034000 -90.0M

Quarterly Revenue Q3/2025:68967000 69.0M, Q2/2025:69387000 69.4M, Q1/2025:68522000 68.5M, Q3/2024:61085000 61.1M, Q2/2024:66909000 66.9M

Quarterly Profit Q3/2025:45841000 45.8M, Q2/2025:45320000 45.3M, Q1/2025:46655000 46.7M, Q3/2024:42862000 42.9M, Q2/2024:46405000 46.4M

Quarterly Net worth Q3/2025:-15737000 -15.7M, Q2/2025:-17142000 -17.1M, Q1/2025:-18892000 -18.9M, Q3/2024:-19170000 -19.2M, Q2/2024:-11350000 -11.4M

Fund house & investment objective

Company Information Evolus, Inc., a performance beauty company, delivers products in the cash-pay aesthetic market in the United States, Canada, Europe, and Australia. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults; and Evolysse, a collection of injectable hyaluronic acid gels. The company was incorporated in 2012 and is headquartered in Newport Beach, California.

Organisation Drug Manufacturers - Specialty & Generic

Employees 329

Industry Drug Manufacturers - Specialty & Generic

CEO Mr. David Moatazedi

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right
style
align-center,button-arrow